Thinking of joining a study?

Register your interest

Become a volunteer?

NCT04993365 | COMPLETED | COVID-19

Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)
Sponsor:

Sinovac Research and Development Co., Ltd.

Brief Summary:

This study is a randomized and controlled phase Ⅳ clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research \& Development Co., Ltd. The purpose of this study is to evaluate the immunogenicity and safety of COVID-19 vaccine (Vero cell), Inactivated co-administration with EV71 vaccine

Condition or disease

COVID-19

Intervention/treatment

Experimental Group

Control Group

Phase

PHASE4

Detailed Description:

This study is a randomized and controlled phase Ⅳ clinical trial in children aged 3-5 years old. The purpose of this study is to evaluate the immunogenicity and safety of COVID-19 vaccine (Vero cell), Inactivated co-administration with EV71 vaccine.The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.A total of 520 subjects aged 3-5 years old will be enrolled.Subjects will be randomly divided into 2 groups in a ratio of 1:1.The experimental group is the combined immunization group, which will receive the first dose of COVID-19 vaccine and the second dose of COVID-19 vaccine and EV71 vaccine on day 28;Control group is the Non-combined immunization group , which will receive the first dose of COVID-19 vaccine on day 0 ，the first dose of EV71 vaccine on day 14 ，the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.

Study Type : INTERVENTIONAL
Estimated Enrollment : 520 participants
Masking : NONE
Primary Purpose : PREVENTION
Official Title : A Randomized and Controlled Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Co-administrated With EV71 Vaccine (Vero Cell) in Children Aged 3-5 Years Old
Actual Study Start Date : 2021-11-05
Estimated Primary Completion Date : 2022-07-14
Estimated Study Completion Date : 2022-07-14

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 3 Years to 5 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: 1
Criteria
Inclusion Criteria
  • * Children aged 3-5 years ;
  • * The subject and/or guardian can understand and voluntarily sign the informed consent form
  • * Proven legal identity;
Exclusion Criteria
  • * History of contact with a SARS-CoV-2 infection (positive in nucleic acid test) within 14 days;
  • * History of multiple system inflammatory syndrome (MIS-C);
  • * History of hand, foot and mouth disease, herpetic angina or EV71 vaccination;
  • * History of asthma, history of allergy to the vaccine or vaccine components,or serious adverse reactions to the vaccine, such as urticaria, dyspnea,and angioedema;
  • * Congenital malformations or developmental disorders, genetic defects,severe malnutrition, etc.;
  • * Autoimmune disease (Systemic lupus erythematosus)or immunodeficiency / immunosuppression(HIV,history after organ transplantation)；
  • * Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.;
  • * Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
  • * Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition;
  • * Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy,abnormal platelets) or obvious bruising or blood coagulation;
  • * Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
  • * History of drug abuse;
  • * Receipt of blood products within in the past 3 months;
  • * Receipt of other investigational drugs in the past 30 days;
  • * Receipt of attenuated live vaccines in the past 14 days;
  • * Receipt of inactivated or subunit vaccines in the past 7 days;
  • * Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
  • * Axillary temperature \>37.0°C;
  • * The subjects participated in other clinical trials during the follow-up period, or will be planned within 3 months;
  • * According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

Location Details

NCT04993365

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

China, Guangdong

Yangchun Center for Disease Control and Prevention

yang Pure, Guangdong, China, 529699

Not yet recruiting

China, Guangdong

Zhanjiang Center for Disease Control and Prevention

Zhanjiang, Guangdong, China, 524005